Drug-induced hyperkalemia: Old culprits and new offenders

American Journal of Medicine

Volumn 109, Issue 4, 2000, Pages 307-314

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMINO ACID; AMINOCAPROIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEPARIN; HYDROCHLOROTHIAZIDE; LABETALOL; LOSARTAN; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; SUXAMETHONIUM; TRIAMTERENE; TRIMETHOPRIM; TSUKUBAENOLIDE;

DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; DRUG OVERDOSE; HUMAN; HYPERKALEMIA; KALIURESIS; KIDNEY FAILURE; NONHUMAN; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL; POTASSIUM METABOLISM; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

DIETARY SUPPLEMENTS; DRUGS, NON-PRESCRIPTION; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY; MALE; PHARMACEUTICAL PREPARATIONS; POTASSIUM; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT;

EID: 0033825899     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00496-4     Document Type: Review

References (80)

1. DeFronzo R.A. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 17:1980;118-134.
2. Perazella M.A., Mahnensmith R.L. Hyperkalemia in the elderly drugs exacerbate impaired potassium homeostasis . J Gen Intern Med. 12:1997;646-656.
3. Batlle D.C., Arruda J.A., Kurtzman N.A. Hyperkalemic distal tubular acidosis associated with obstructive uropathy. NEJM. 304:1981;373-380.
4. Rastegar A, DeFronzo RA. Disorders of potassium and acid-base metabolism in association with renal disease. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. New York: Little, Brown and Company, 1997:2451-2475.
5. Shemer J., Ezra D., Modan M., Cabili S. Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci. 19:1983;659-661.
6. Paice B., Gray J.M.B., McBride D., Lawson D.H. Hyperkalemia in patients in hospital. BMJ. 286:1983;1189-1192.
7. Shapiro S., Slone D., Lewis G.P., Jick H. Fatal drug reactions among medical inpatients. J Am Med Assoc. 216:1971;467-472.
8. Acker C.G., Johnson J.P., Palevsky P.M., Greenberg A. Hyperkalemia in hospitalized patients. Arch Intern Med. 158:1998;917-924.
9. Borra S., Shaker R., Kleinfeld M. Hyperkalemia in an adult hospitalized population. Mt Sinai J Med. 55:1988;226-229.
10. Moore M.L., Bailey R.R. Hyperkalaemia in patients in hospital. N Z Med J. 102:1989;557-558.
11. Ahmed E.U., Mohammed B.N., Matute R., Burns G.C. Etiology of hyperkalemia in hospitalized patients an answer to Harrinton's question . J Am Soc Nephrol. 9:1998;103A.
12. Lawson D.H. Adverse reactions to potassium chloride. Q J Med. 43:1974;433-440.
13. Lawson DH, O'Connor PC, Jick H. Drug attributed alterations in potassium handling in congestive heart failure. Eur J Clin Pharmacol. 1982;23:21-25.
14. Rimmer J.M., Horn J.F., Gennari F.J. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 147:1987;867-869.
15. Ponce S.P., Jennings A.E., Madias N.E., Harrington J.T. Drug-induced hyperkalemia. Medicine. 64:1985;357-370.
16. McCaughan D. Hazards of non-prescription potassium supplements. Lancet. 1:1984;513-514.
17. Mueller B.A., Scott M.K., Sowinski K.M., Prag K.A. Noni juice (Morinda citrifolia). Am J Kidney Dis. 35:2000;310-312.
18. Browning J.J., Channer K.S. Hyperkalaemic cardiac arrhythmia caused by potassium citrate mixture. BMJ. 283:1981;1366-1368.
19. Michael J.M., Dorner I., Burns D., et al. Potassium load in CPD-preserved whole blood and two types of packed red cells. Transfusion. 15:1975;144-149.
20. Mercer C.W., Logic J.R. Cardiac arrest due to hyperkalemia following intravenous penicillin administration. Chest. 64:1973;358-359.
21. Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand. 672:(suppl):1983;121-132.
22. Rosa R.M., Silva P., Young J.B., et al. Adrenergic modulation of extrarenal potassium disposal. NEJM. 302:1980;431-434.
23. Ewart H.S., Klip A. Hormonal regulation of the Na+-K+-ATPase mechanisms underlying rapid and sustained changes in pump activity . Am J Physiol. 269:1995;C295-C311.
24. Traub Y.M., Rabinov M., Rosenfeld J.B., Treuherz S. Elevation of serum potassium during beta-blockade absence of relationship to the renin-aldosterone system . Clin Pharmacol Ther. 28:1980;765-768.
25. Arthur S., Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 33:1990;269-271.
26. Levinsky N.G., Tyson I., Miller R.B., Relman A.S. The relationship between amino acids and potassium in isolated rat muscle. J Clin Invest. 41:1962;480-487.
27. Dickerman H.W., Walker W.G. Effect of cationic amino acids infusion on potassium metabolism in vivo. Am J Physiol. 206:1964;403-408.
28. Hertz P., Richardson J.A. Arginine-induced hyperkalemia. Arch Intern Med. 130:1972;778-780.
29. Bushinsky D.A., Gennari F.J. Life-threatening hyperkalemia induced by arginine. Ann Intern Med. 89:1978;632-634.
30. Carroll H.J., Tice D.A. The effects of epsilon aminocaproic acid upon potassium metabolism in the dog. Metabolism. 15:1966;449-457.
31. Perazella M.A., Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis. 33:1999;782-785.
32. Perazella M.A., Garwood S., Matthew J., et al. Hyperkalemia associated with IV epsilon-aminocaproic acid. J Am Soc Nephrol. 10:1999;123A.
33. Weintraub H.D., Heisterkamp D.V., Cooperman L.H. Changes in plasma potassium concentration after depolarizing blockers in anaesthetized man. B J Anaesth. 41:1969;1048-1052.
34. Yentis S.M. Suxamethonium and hyperkalaemia. Anaesth Intensive Care. 18:1990;92-101.
35. Lown B., Black H., Moore F.D. Digitalis, electrolytes and the surgical patient. Am J Cardiol. 6:1960;309-337.
36. Smith T.W., Willerson J.T. Suicidal and accidental digoxin ingestion. Report of five cases with serum digoxin level correlations. Circulation. 44:1971;29-36.
37. Ramsay L.E., Hettiarachchi J., Fraser R. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol. 4:1980;533-543.
38. Greenblatt D.J., Koch-Weser J. Adverse reactions to spironolactone. J Am Med Assoc. 225:1973;40-43.
39. McDonald C.J. Dyazide and hyperkalemia. Ann Intern Med. 84:1976;612-613.
40. Chiu T.F., Bullard M.J., Chen J.C., et al. Rapid life-threatening hyperkalemia after addition of amiloride Hcl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 30:1997;612-615.
41. Henger A., Tutt P., Hulter H.N., Krapf R. Acid-base effects of inhibition of aldosterone and angiotensin II action in chronic metabolic acidosis in humans. J Am Soc Nephrol. 10:1999;121A.
42. Feinfeld D.A., Carvounis C.P. Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment. . J Am Med Assoc. 240:1978;1516.
43. McNay J.L., Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretics, amiloride (MK-870). Metabolism. 19:1970;58-70.
44. Papadimitriou M., Vyzantiadis A., Milionis A., Memmos D., Metaxas P. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Systems. 1:1983;197-206.
45. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 44:1993;643-653.
46. Garella S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 63:1984;165-181.
47. Tan S.Y., Shapiro R., Franco R., et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med. 90:1979;783-785.
48. Zimran A., Kramer M., Plaskin M., et al. Incidence of hyperkalaemia induced by indomethacin in a hospital population. BMJ. 291:1985;107-108.
49. Kimberly R.P., Bowden R.E., Keiser H.R., et al. Reduction of renal function by newer non-steroidal antiinflammatory drugs. Am J Med. 64:1978;804-806.
50. Perazella M.A., Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis. 35:2000;937-940.
51. Textor S.C., Bravo E.L., Fouad F.M., et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med. 73:1982;719-725.
52. Atlas S.A., Case D.B., Sealey J.E., et al. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension. 1:1979;274-280.
53. Memon A., Siddiqui M., Agraharkar M., Ahuja T. Incidence and predictors of hyperkalemia in patients with chronic renal failure on angiotensin converting enzyme inhibitors. J Am Soc Nephrol. 10:1999;294A.
54. Reardon L.C., Macpherson D.S. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. Arch Intern Med. 158:1998;26-32.
55. Keilani T., Danesh F.R., Schlueter W.A., et al. A subpressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis. 33:1999;450-457.
56. Heeg J.E., deJong P.E., Vriesendorp R., deZeeuw D. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol. 10:1990;94-97.
57. Dahlstrom U., Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol. 71:1993;29A.
58. Hannedouche T., Landais P., Goldfarb B., et al. Randomised controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure. BMJ. 309:1994;833-837.
59. Goldberg M.R., Bradstreet T.E., McWilliams E.J., et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 25:1995;37-46.
60. Goldberg A.I., Dunlay M.C., Sweet C.S. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
61. Savoy A., Palant C.E., Patchin G., Graettinger W.F. Losartan effects on serum potassium in an elderly population. J Am Soc Nephrol. 9:1998;111A.
62. Bakris G.L., Siomas M., Bolton W.K., et al. Differential effects of valsartan and lisinopril on potassium homeostasis in hypertensive patients with nephropathy. J Am Soc Nephrol. 10:1999;68A.
63. Velázquez H., Perazella M.A., Wright F.S., Ellison D.H. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 119:1993;296-301.
64. Schreiber M., Schlanger L.E., Chen C.B., et al. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int. 49:1996;82-87.
65. Kaufman A.M., Hellman G., Abramson R.G. Renal salt wasting and metabolic acidosis with trimethoprim-sulfamethoxazole therapy. Mt Sinai J Med. 50:1983;238-239.
66. Alappan R., Perazella M.A., Buller G.K. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 124:1996;316-320.
67. Alappan R., Buller G.K., Perazella M.A. Trimethoprim-sulfamethoxazole therapy in outpatients is hyperkalemia a significant problem . Am J Nephrol. 19:1999;389-394.
68. Lachaal M., Venuto R.C. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 87:1989;260-263.
69. Briceland L.L., Bailie G.R. Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. DICP. 25:1991;1171-1175.
70. Heering P., Grabanese B. Influence of cyclosporine A on renal tubular function after kidney transplantation. Nephron. 59:1991;66-70.
71. Kamel K.S., Ethier J.H., Quaggin S., et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol. 2:1992;1279-1284.
72. Tumlin J.A., Sands J.M. Nephron segment-specific inhibition of Na+/K+-ATPase activity by cyclosporin A. Kidney Int. 43:1993;246-251.
73. Lea J.P., Sands J.M., McMahon S.J., Tumlin J.A. Evidence that the inhibition of Na+/K+-ATPase activity by FK506 involves calcineurin. Kidney Int. 46:1994;647-652.
74. Ling B.N., Eaton D.C. Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells. Kidney Int. 44:1993;974-984.
75. Pei Y., Richardson R., Greenwood C., Math M., Wong P.Y., Baines A. Extrarenal effect of cyclosporine A on potassium homeostasis in renal transplant recipients. Am J Kidney Dis. 22:1993;314-319.
76. Yu H.S., Chang H.S., Han D.J., et al. Change of transtubular potassium gradient (TTKG) in renal transplant recipients. J Am Soc Nephrol. 10:1999;14A.
77. Kaplan B., Wang Z., Abecassis M.M., et al. Frequency of hyperkalemia of simultaneous pancreas and kidney transplants with bladder drainage. Transplantation. 62:1996;1174-1175.
78. Assante-Korang A., Boyle G.J., Webber S.A., et al. Experience of FK506 immune suppression in pediatric heart transplantation a study of long term adverse effects . J Heart Lung Transplant. 15:1996;415-422.
79. Woo M., Przepiorka D., Ippoliti C., et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 20:1997;1095-1098.
80. Oster J.R., Singer I., Fishman L.M. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 98:1995;575-586.